Open AccessPrognostic value of quantitative FDG‑PET in the prediction of survival and local recurrence for patients with advanced oral cancer treated with superselective intra‑arterial chemoradiotherapy
Author(s) -
Tomoyuki Oyama,
Yoichiro Hosokawa,
Kazuki Abe,
Kazuki Hasegawa,
Roh Fukui,
Masahiko Aoki,
Wataru Kobayashi
Publication year - 2020
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2020.11488
Subject(s) - medicine , nedaplatin , standardized uptake value , cancer , chemoradiotherapy , docetaxel , nuclear medicine , positron emission tomography , radiation therapy , urology , chemotherapy , radiology , cisplatin
The current study aimed to evaluate the relationship between 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET-CT) standardized uptake value (SUV) [pre-treatment SUV (pre-SUV) and post-treatment SUV (post-SUV)] and treatment results in patients with advanced oral cancer treated with superselective intra-arterial chemoradiotherapy (SSIACRT). A total of 37 patients with advanced oral cancer were treated with SSIACRT. The treatment consisted of superselective intra-arterial chemotherapy (docetaxel (DOC) 40 mg/mm 2 and nedaplatin (CDGP) 80 mg/mm 2 ) and concurrent radiotherapy (60-70 Gy) for a period of seven weeks. Pre-SUV and post-SUV of the primary tumor were measured. Overall survival (OS) and local control (LC) rates were selected as endpoints to evaluate prognosis. The median follow-up was 40 months (range 6-112 months). The 5-year OS and LC rates were 64.5 and 85.5%, respectively, and SSIACRT achieved high LC rate even in advanced oral cancers. In the log-rank test, post-SUV was a significant prognostic factor for OS and LC rates. The results of the current study demonstrated that SSIACRT is a reliable treatment with respect to survival in advanced oral cancer and post-SUV was a significant prognostic factor for OS and LC rates.